PremiumCompany AnnouncementsGenmab Reports Strong Q1 2025 Earnings Growth Genmab Reports Strong Q1 2025 Financial Results and Product Approvals Genmab reports Q1 revenue $715M vs. $603M last year PremiumThe FlyGenmab price target lowered to DKK 1,990 from DKK 2,970 at HSBC Genmab’s Strong Market Position and Growth Potential Justifies Buy Rating Genmab Advances Share Buy-back Program with Significant Repurchases PremiumCompany AnnouncementsGenmab Announces Share Capital Reduction Following AGM Decision Genmab price target lowered to $37 from $50 at H.C. Wainwright Genmab’s Strong Financial Performance and Strategic Positioning Justify Buy Rating Despite Minor Setbacks